<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285255</url>
  </required_header>
  <id_info>
    <org_study_id>OFA</org_study_id>
    <nct_id>NCT04285255</nct_id>
  </id_info>
  <brief_title>Quality of Recovery Following Opioids Free Anaesthesia in Laparoscopic Sleeve Gastrectomy</brief_title>
  <official_title>Quality of Recovery of Opioid Free Anaesthesia Versus Opioids Anaesthesia Within Enhanced Recovery Protocol Following Laparoscopic Sleeve Gastrectomy in Saudi Arabia, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Al Mashfa Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Al Mashfa Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Laparoscopic sleeve gastrectomy is widely employed nowadays. Multimodal analgesia approach is&#xD;
      implemented within the enhanced recovery protocol in our facility to improve participants'&#xD;
      recovery. Due to side effects of narcotics, the may adversely affect the quality of recovery,&#xD;
      the investigators intended to test the efficacy of opioids free anaesthesia on the quality of&#xD;
      recovery and postoperative narcotic use.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Actual">August 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>only the anaesthetist is one aware of the study groups</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of recovery 40 questionnaire (QoR-40)</measure>
    <time_frame>At 6 hours</time_frame>
    <description>postoperative quality of recovery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of recovery 40 questionnaire (QoR-40)</measure>
    <time_frame>At 24th h (period of time between 6 and 24 hours) as repeated measurement</time_frame>
    <description>postoperative quality of recovery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pethidine consumption</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical rating scale (NRS)</measure>
    <time_frame>24 hours</time_frame>
    <description>visual analogue scale postoperatively</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Narcotics</condition>
  <condition>Recovery Quality</condition>
  <condition>Analgesia</condition>
  <condition>Bariatric Surgery</condition>
  <arm_group>
    <arm_group_label>Opioids anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received propofol-fentanyl induction of anaesthesia plus ultrasound-guided Bilateral oblique subcostal TAP block using 20ml of bupivacaine hydrochloride 0.25% (Marcaine, Astra Zeneca UK) in each side (total volume of 40 ml) deposited equally on each side</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OFA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received preinduction with dexmeditomidine 0.1µg.kg-1 over 10 min. Induction with propofol 1.5 mg.kg-1-ketamine (ketofol 3:1 mixture) induction plus maintenance mixture of dexmedetomidine 0.5µg.kg-1.h-1, ketamine 0.5mg.kg-1.h-1, and lidocaine 1 mg.kg-1.h-1 plus ultrasound-guided Bilateral oblique subcostal TAP block using 20ml of bupivacaine hydrochloride 0.25% (Marcaine, Astra Zeneca UK) in each side (total volume of 40 ml) deposited equally on each side</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>opioids anaesthesia</description>
    <arm_group_label>Opioids anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>ketamine induction and analgesia as opioids free anaesthesia versus opioids analgesia</description>
    <arm_group_label>OFA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Injection [Precedex]</intervention_name>
    <description>alpha 2 agonist with sedative, analgesic effect</description>
    <arm_group_label>OFA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Oblique subcostal transversus abdominis plane block</intervention_name>
    <description>Bupivacaine 0.25% injected under ultrasound usage in the transversus abdominis plane</description>
    <arm_group_label>OFA</arm_group_label>
    <arm_group_label>Opioids anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>infusion of lidocaine 2%(1mg/kg/h)</description>
    <arm_group_label>OFA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  70 ASA II - III adult patients (18-60 years old)&#xD;
&#xD;
          -  Elective laparoscopic bariatric surgery.&#xD;
&#xD;
          -  Body mass index (BMI) is from 40 to 60&#xD;
&#xD;
          -  Trocar sites at or above the umbilicus (T 10 dermatome).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to amino-amide local anaesthetics,&#xD;
&#xD;
          -  presence of coagulopathy&#xD;
&#xD;
          -  local skin infection at injection sites,&#xD;
&#xD;
          -  preoperative chronic dependence upon opioid and NSAID medications,&#xD;
&#xD;
          -  liver or renal insufficiency,&#xD;
&#xD;
          -  history of psychiatric or neurological disease, deafness,&#xD;
&#xD;
          -  previous open surgery,&#xD;
&#xD;
          -  patients who need to be converted to open surgery with more tissue trauma,&#xD;
&#xD;
          -  ASA (American society of anesthesiologists) class above III were excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Al Mashfa medical center</name>
      <address>
        <city>Khobar</city>
        <state>Eastern Provence</state>
        <zip>34225/7564</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 22, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>October 30, 2021</last_update_submitted>
  <last_update_submitted_qc>October 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

